Pfizer/ BioNTech’s jointly developed COVID-19 vaccine emerges extremely effective against the virus in a study that was conducted among 1.2 million Israeli people, Bloomberg reports, citing a study conducted by the teams from the Clalit Research Institute and Harvard University.
Additional details
“Two doses of the vaccine prevented 94% of Covid-19 cases in 596,618 people vaccinated between Dec. 20 and Feb. 1, about one-quarter of whom were over the age of 60.”
“After two doses, the vaccine was just as effective for adults age 70 and older as it was for younger people. There were indications that the shot might work slightly less well for people who were sick with three or more other illnesses, such as high blood pressure and diabetes.”
“But the benefit remained strong, with 89% protection from Covid symptoms seven days after the second dose. And for most people, protection was already significant two to three weeks after the first dose.”
Market reaction
The encouraging vaccine news could likely add to the reflation trade-optimism, as the S&P 500 futures rise 0.19% to 3,930 levels.
作者：Dhwani Mehta，文章来源FXStreet，版权归原作者所有，如有侵权请联系本人删除。
风险提示：以上内容仅代表作者或嘉宾的观点，不代表 FOLLOWME 的任何观点及立场，且不代表 FOLLOWME 同意其说法或描述，也不构成任何投资建议。对于访问者根据 FOLLOWME 社区提供的信息所做出的一切行为，除非另有明确的书面承诺文件，否则本社区不承担任何形式的责任。
FOLLOWME 交易社区网址: www.followme.ceo
加载失败()